New drug hopes to slow kidney damage in FSGS patients
NCT ID NCT07268638
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a new drug, praliciguat, for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). About 60 adults will be randomly assigned to take either the drug or a placebo for 24 weeks, followed by 24 weeks where everyone gets the drug. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigator Site # 1
RECRUITINGLawrenceville, Georgia, 30046, United States
-
Investigator Site #10
RECRUITINGPontiac, Michigan, 48341, United States
-
Investigator Site #2
RECRUITINGChula Vista, California, 91910, United States
-
Investigator Site #3
RECRUITINGChicago, Illinois, 60643, United States
-
Investigator Site #4
RECRUITINGChattanooga, Tennessee, 37404, United States
-
Investigator Site #5
RECRUITINGArlington, Texas, 76015, United States
-
Investigator Site #6
RECRUITINGCoral Springs, Florida, 33071, United States
-
Investigator Site #7
RECRUITINGMiami, Florida, 33172, United States
-
Investigator Site #8
RECRUITINGOrlando, Florida, 32806, United States
-
Investigator Site #9
RECRUITINGDallas, Texas, 75231, United States
Conditions
Explore the condition pages connected to this study.